Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 10Solid Tumors 8Solid Tumor 8Unspecified Adult Solid Tumor, Protocol Specific 7Mesothelioma 6Mesothelioma, Malignant 3Advanced Solid Tumor 3Advanced/Metastatic Solid Tumors 2Advanced Solid Tumour 2Uterine Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor 1Triple Negative Breast Neoplasms 1Solitary Fibrous Tumor, Pleural 1Solid Tumor, Adult 1Select Advanced Solid Tumors 1Refractory Solid Tumors in Children 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Malignant Solid Tumour 1MSI-H Advanced Colorectal Cancer 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Cervical Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Advanced HCC 1

Interventions

Vorinostat 2pembrolizumab 1nintedanib 1dactolisib 1avelumab 1Vinorelbine 1Sunitinib 1Oxaliplatin 1Levoleucovorin 1Leucovorin 1Hydroxychloroquine 1Folfox protocol 1Fluorouracil 1Dasatinib 1DOXO-EMCH 1Cetuximab 1Bevacizumab 1BN 80927 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumour × Bevacizumab × Other solid neoplasm × Clear all
NCT02857920 2020-09-14

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Completed
45 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡